Are they giving this to Generex or NGIO? It says Generex but they include NGIO in the 8K also.
Edit: How do they do the valuation on this, if they are writing this as saying to Generex for these deals?
Item 1.01 Entry into a Material Definitive Agreement.
On December 15, 2020, Generex Biotechnology Corporation and its majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) agreed and signed an extension for the receipt of the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment from the “Joint Entity” (the “Extension Agreement”) as set forth under the Ii-Key Innovative Vaccine Development Agreement signed November 13, 2020 (the “Agreement”), with Beijing Youfeng International Consulting Co., Ltd (“BYIC”), National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention (“NIVDC”) and Beijing Guoxin Haixiang Equity Investment Partnership (“BGHEIP” and together with BYIC and NIVDC, the “China Partners”) to set up a joint research team and a joint entity in China (the “Joint Entity”) that shall jointly develop and industrialize the Generex internationally patented Ii-Key innovative technology for a SARS-CoV-2 coronavirus peptide vaccine (the “Vaccine”) and other vaccines in the People’s Republic of China (“China”) and for Generex to provide the Joint Entity with an exclusive license to use its intellectual property; technical know-how, pre-clinical and clinical data and background materials, in each case, relating to Ii-Key-SARS-CoV-2 technology in the People’s Republic of China, including Hong Kong Special Administrative Region and Macau Special Administrative Region, but excluding the Islands of Taiwan (the “Licensed Territory”).
The Extension Agreement allows for the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment to be made to Generex no later than before December 31, 2020.
This Current Report contains summaries of the material terms of the Extension Agreement. The summary of the Extension Agreement contained in this Current Report is subject to, and is qualified in its entirety by, reference to the Extension Agreement, which is filed as an exhibit hereto and incorporated herein by reference.
A copy of the Extension Agreement signed December 15, 2020, is filed as Exhibit 99.1 to this Current Report.
Edit: How do they do the valuation on this, if they are writing this as saying to Generex for these deals?
Item 1.01 Entry into a Material Definitive Agreement.
On December 15, 2020, Generex Biotechnology Corporation and its majority owned entity NuGenerex Immuno-Oncology, Inc., (collectively “Generex”) agreed and signed an extension for the receipt of the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment from the “Joint Entity” (the “Extension Agreement”) as set forth under the Ii-Key Innovative Vaccine Development Agreement signed November 13, 2020 (the “Agreement”), with Beijing Youfeng International Consulting Co., Ltd (“BYIC”), National Institute for Viral Disease Control and Prevention, Chinese Centre for Disease Control and Prevention (“NIVDC”) and Beijing Guoxin Haixiang Equity Investment Partnership (“BGHEIP” and together with BYIC and NIVDC, the “China Partners”) to set up a joint research team and a joint entity in China (the “Joint Entity”) that shall jointly develop and industrialize the Generex internationally patented Ii-Key innovative technology for a SARS-CoV-2 coronavirus peptide vaccine (the “Vaccine”) and other vaccines in the People’s Republic of China (“China”) and for Generex to provide the Joint Entity with an exclusive license to use its intellectual property; technical know-how, pre-clinical and clinical data and background materials, in each case, relating to Ii-Key-SARS-CoV-2 technology in the People’s Republic of China, including Hong Kong Special Administrative Region and Macau Special Administrative Region, but excluding the Islands of Taiwan (the “Licensed Territory”).
The Extension Agreement allows for the Five Million Dollar USD ($5,000,000.00) upfront licensing fee payment to be made to Generex no later than before December 31, 2020.
This Current Report contains summaries of the material terms of the Extension Agreement. The summary of the Extension Agreement contained in this Current Report is subject to, and is qualified in its entirety by, reference to the Extension Agreement, which is filed as an exhibit hereto and incorporated herein by reference.
A copy of the Extension Agreement signed December 15, 2020, is filed as Exhibit 99.1 to this Current Report.
